- Home
- UFI vs PRLD Comparison
UFI vs PRLD Comparison
Compare UFI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFI
- PRLD
- Stock Information
- Founded
- UFI 1969
- PRLD 2016
- Country
- UFI United States
- PRLD United States
- Employees
- UFI N/A
- PRLD N/A
- Industry
- UFI Textiles
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- UFI Consumer Discretionary
- PRLD Health Care
- Exchange
- UFI Nasdaq
- PRLD Nasdaq
- Market Cap
- UFI 85.7M
- PRLD 73.7M
- IPO Year
- UFI N/A
- PRLD 2020
- Fundamental
- Price
- UFI $5.30
- PRLD $0.81
- Analyst Decision
- UFI
- PRLD Strong Buy
- Analyst Count
- UFI 0
- PRLD 2
- Target Price
- UFI N/A
- PRLD $4.50
- AVG Volume (30 Days)
- UFI 68.7K
- PRLD 279.1K
- Earning Date
- UFI 05-07-2025
- PRLD 05-06-2025
- Dividend Yield
- UFI N/A
- PRLD N/A
- EPS Growth
- UFI N/A
- PRLD N/A
- EPS
- UFI N/A
- PRLD N/A
- Revenue
- UFI $592,700,000.00
- PRLD $7,000,000.00
- Revenue This Year
- UFI $1.03
- PRLD N/A
- Revenue Next Year
- UFI $18.80
- PRLD N/A
- P/E Ratio
- UFI N/A
- PRLD N/A
- Revenue Growth
- UFI 1.57
- PRLD N/A
- 52 Week Low
- UFI $4.25
- PRLD $0.61
- 52 Week High
- UFI $7.91
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- UFI 59.22
- PRLD 57.52
- Support Level
- UFI $4.57
- PRLD $0.71
- Resistance Level
- UFI $4.92
- PRLD $0.72
- Average True Range (ATR)
- UFI 0.27
- PRLD 0.08
- MACD
- UFI 0.07
- PRLD 0.02
- Stochastic Oscillator
- UFI 73.43
- PRLD 76.92
About UFI Unifi Inc. New
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.